PE20001022A1 - Compuestos de pirazina - Google Patents

Compuestos de pirazina

Info

Publication number
PE20001022A1
PE20001022A1 PE1999000868A PE00086899A PE20001022A1 PE 20001022 A1 PE20001022 A1 PE 20001022A1 PE 1999000868 A PE1999000868 A PE 1999000868A PE 00086899 A PE00086899 A PE 00086899A PE 20001022 A1 PE20001022 A1 PE 20001022A1
Authority
PE
Peru
Prior art keywords
disorders
pirazine
compounds
alkyl
refers
Prior art date
Application number
PE1999000868A
Other languages
English (en)
Inventor
Brian Cox
Mark Patrick Healy
Deborah Wild
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20001022A1 publication Critical patent/PE20001022A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DE PIRAZINA DE FORMULA I, DONDE R1 ES FENILO SUSTITUIDO POR HALOGENO DE PREFERENCIA TRICLOROFENILO; R2 ES NH2; R3 ES NH2, H; R4 ES CXNRaRb, CXNH-(CH2)y-NRaRb; X ES =O, =S; y ES 0-2; Ra Y Rb SON H, ALQUILO C1-C4 O JUNTO CON N FORMAN UN HETEROCICLO DE 5-6 MIEMBROS CON 1-2 N OPCIONALMENTE SUSTITUIDOS CON UNO O MAS ALQUILO C1-C4. UN COMPUESTO PREFERIDO ES 2,6-DIAMINO-5-CARBOXAMIDO-3-(2,3,5-TRICLOROFENIL)PIRAZINA. TAMBIEN SE REFIERE A UN PROCESO PARA LA PREPARACION. EL COMPUESTO I ES UN BLOQUEADOR DEL CANAL DE SODIO Y PUEDE SER UTIL PARA EL TRATAMIENTO DE EPILEPSIA, TRASTORNO BIPOLAR, DEPRESION MANIACA, DEPRESION UNIPOLAR, DOLOR, TRASTORNOS EN LA FUNCION DEL INTESTINO, TRASTORNOS NEURODEGENERATIVOS, NEUROPROTECCION, NEURODEGENERACION, ZUMBIDO DEL OIDO; TOLERANCIA INVERSA, UN AGENTE INDUCTOR DE DEPENDENCIA
PE1999000868A 1998-08-28 1999-08-26 Compuestos de pirazina PE20001022A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9818881.6A GB9818881D0 (en) 1998-08-28 1998-08-28 Compounds

Publications (1)

Publication Number Publication Date
PE20001022A1 true PE20001022A1 (es) 2000-10-16

Family

ID=10838055

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000868A PE20001022A1 (es) 1998-08-28 1999-08-26 Compuestos de pirazina

Country Status (15)

Country Link
US (2) US6503909B1 (es)
EP (1) EP1107960A1 (es)
JP (1) JP2002523499A (es)
KR (1) KR20010079696A (es)
CN (1) CN1324349A (es)
AU (1) AU5624999A (es)
BR (1) BR9913183A (es)
CA (1) CA2341543A1 (es)
CO (1) CO5130006A1 (es)
GB (1) GB9818881D0 (es)
MA (1) MA26681A1 (es)
PE (1) PE20001022A1 (es)
TR (1) TR200100603T2 (es)
TW (1) TW429255B (es)
WO (1) WO2000012488A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006938B1 (ru) 2000-02-16 2006-06-30 Ньюроджин Корпорейшн Замещенные арилпиразины
EP1500653A1 (en) * 2000-02-16 2005-01-26 Neurogen Corporation Substituted arylpyrazines
GB0010971D0 (en) * 2000-05-05 2000-06-28 Glaxo Group Ltd Process
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
JP4901102B2 (ja) * 2002-05-03 2012-03-21 エクセリクシス， インク． プロテインキナーゼモジュレーターおよびその使用方法
JP2006509729A (ja) 2002-08-20 2006-03-23 ニューロジェン・コーポレーション Ｃｒｆ受容体モジュレータとしての５−置換−２−アリールピラジン類
CA2529623A1 (en) * 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US20070287677A1 (en) * 2004-03-30 2007-12-13 Genomldea Inc. Rad51 Expression Inhibitors, Pharmaceutical Agents Containing The Inhibitors As Active Ingredients, And Uses Thereof
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP2094731A2 (en) * 2006-11-10 2009-09-02 UCB Pharma S.A. Anti human sclerostin antibodies
EP2097450A2 (en) * 2006-11-10 2009-09-09 Amgen Inc. Antibody-based diagnostics and therapeutics
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
KR20100101656A (ko) * 2007-12-14 2010-09-17 암젠 인크 항-스클레로스틴 항체를 사용한 골절 치료 방법
KR20230135541A (ko) * 2022-03-16 2023-09-25 (주)아름테라퓨틱스 신규한 화합물 및 이의 체크포인트 키나제 2 저해 용도
CN115611700B (zh) * 2022-10-11 2024-06-14 辽宁东大光明化工科技有限责任公司 一种1-溴-2,5-二氯-3-氟苯的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3575975A (en) 1968-07-25 1971-04-20 Merck & Co Inc Process for the preparation of 3-aminopyrazinoylureas
US3544568A (en) * 1969-03-18 1970-12-01 Merck & Co Inc 3-amino-5,6-substituted pyrazinamides
US4402958A (en) 1981-11-19 1983-09-06 American Cyanamid Company Novel (substituted phenyl)-1,2,4-triazolo (4,3-A)pyrazines and novel 2-hydrazino-(substituted phenyl)pyrazine intermediates
MA26473A1 (fr) 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.

Also Published As

Publication number Publication date
CO5130006A1 (es) 2002-02-27
AU5624999A (en) 2000-03-21
BR9913183A (pt) 2001-05-15
US20030022904A1 (en) 2003-01-30
CA2341543A1 (en) 2000-03-09
US6503909B1 (en) 2003-01-07
WO2000012488A1 (en) 2000-03-09
KR20010079696A (ko) 2001-08-22
EP1107960A1 (en) 2001-06-20
TW429255B (en) 2001-04-11
TR200100603T2 (tr) 2001-07-23
GB9818881D0 (en) 1998-10-21
JP2002523499A (ja) 2002-07-30
MA26681A1 (fr) 2004-12-20
CN1324349A (zh) 2001-11-28

Similar Documents

Publication Publication Date Title
PE20001022A1 (es) Compuestos de pirazina
PE58299A1 (es) Compuestos de pirazina
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
PE20010647A1 (es) Moduladores de receptores de retinoide x (rxr) con perfil farmacologico mejorado
IL145830A0 (en) Pharmaceutical compositions containing a compound which activates a receptor for glucagon-like peptide-1
DE69936848D1 (de) Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie
AR013477A1 (es) Prostaglandinas de tetrahidro sustituido c16-20 aromatico utiles como agonistas de fp.
PE20001600A1 (es) Derivados de 1,4-diazabiciclo (3.3.2) nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica
PE20050484A1 (es) Composicion farmaceutica de liberacion sostenida
PE20020506A1 (es) Derivados de pirazol fusionados como inhibidores de la proteina cinasa
TW200508180A (en) Therapeutic agents
PE20000337A1 (es) Pirazolpirimidinas y pirazoltriazinas
PE12697A1 (es) Compuestos heterociclicos, su preparacion y su uso
AU3345595A (en) 3-benzoyl benzofuran derivatives as thyroid hormone antagonists
MXPA04005847A (es) Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
PE20001084A1 (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas
RS52724B (en) PREVENTION OF HIV INFECTION WITH TMC278
ATE358474T1 (de) Halogenhaltige zusammensetzung, verfahren zu deren herstellung und deren verwendung
PE83999A1 (es) Azetidinas
DE69528710D1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung
AR033426A1 (es) Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento
HUP9800273A2 (hu) Endotelin antagonista hatású benzotiazin-dioxid-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
PE120099A1 (es) Nueva 3,4-diariltiazolina-2-ona o 2-tiona derivados, sus metodos de preparacion y su uso terapeutico
ES2160649T3 (es) Nuevos compuestos lactamicos y procedimientos para su preparacion.
ES2032570T3 (es) Derivados antiparkinson de ergolina. (reserva del art. 167.2 cpe).

Legal Events

Date Code Title Description
FD Application declared void or lapsed